Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following statements about biotransformation is untrue?

More fat-soluble metabolites are formed.. ### Explanation **Biotransformation** (Drug Metabolism) is the chemical alteration of a drug in the body, primarily occurring in the liver. Its fundamental biological purpose is to convert **lipid-soluble (non-polar)** compounds into **water-soluble (polar)** compounds to facilitate excretion by the kidneys. #### Why Option C is Untrue (The Correct Answer) Metabolism aims to decrease lipid solubility. If metabolites were more fat-soluble, they would be reabsorbed by the renal tubules back into the systemic circulation, leading to drug accumulation and toxicity. Therefore, the formation of more fat-soluble metabolites is incorrect. #### Analysis of Other Options * **A & B: Inactive and Active metabolites are formed:** Most drugs are inactivated by metabolism (e.g., Paracetamol). However, some drugs are converted into **active metabolites** (e.g., Diazepam to Oxazepam) or are administered as **Prodrugs** (e.g., Enalapril to Enalaprilat), where metabolism is required for activation. * **D: More water-soluble metabolites are formed:** This is the primary goal of Phase I (Functionalization) and Phase II (Conjugation) reactions. Increasing polarity ensures the drug can be easily excreted in urine or bile. #### NEET-PG High-Yield Pearls * **Phase I Reactions:** Include Oxidation (most common), Reduction, and Hydrolysis. These primarily involve the **Cytochrome P450** enzyme system. * **Phase II Reactions:** Include Glucuronidation (most common), Acetylation, and Methylation. These usually result in total inactivation. * **Exception to the Rule:** Morphine-6-glucuronide is a rare example of a Phase II metabolite that is *more* active than the parent drug. * **First-Pass Metabolism:** Drugs with high first-pass metabolism (e.g., Nitroglycerin, Lidocaine) have low oral bioavailability.

Q: Which of the following drugs has the least oral bioavailability?

d-tubocurarine. **Explanation:** The correct answer is **d-tubocurarine (Option A)**. **1. Why d-tubocurarine is correct:** Bioavailability is the fraction of an administered drug that reaches the systemic circulation in an unchanged form. **d-tubocurarine** is a quaternary ammonium compound. Due to its strong positive charge, it is highly ionized at all physiological pH levels. Highly ionized drugs are **lipid-insoluble**, meaning they cannot cross the lipid bilayer of the gastrointestinal tract. Consequently, its oral bioavailability is nearly **zero**, necessitating intravenous administration for its effect as a neuromuscular blocker. **2. Why the other options are incorrect:** * **Morphine (B):** While morphine undergoes significant **first-pass metabolism** in the liver (reducing its bioavailability to ~25-30%), it is still absorbed from the gut and can be administered orally for chronic pain management. * **Ampicillin (C):** This is an acid-stable penicillin. Although its absorption is incomplete and can be decreased by food, it has a bioavailability of approximately 30-50%, making it effective via the oral route. * **Phenytoin (D):** This antiepileptic drug has high oral bioavailability (approx. 70-90%), though it exhibits slow and variable absorption. **3. Clinical Pearls for NEET-PG:** * **Quaternary Ammonium Compounds:** Drugs like d-tubocurarine, neostigmine, and ipratropium are permanently charged; they do not cross the GI tract or the Blood-Brain Barrier (BBB). * **First-Pass Effect:** High first-pass metabolism (e.g., Nitroglycerin, Lidocaine, Morphine) is a common reason for low bioavailability, but **poor lipid solubility** (e.g., Aminoglycosides, d-tubocurarine) results in the *least* oral absorption. * **Bioavailability (F):** For IV administration, F = 100% (or 1). For all other routes, F < 1.

Q: The time required to reach the steady state after a dosage regimen depends on which of the following?

Half-life of the drug. ### Explanation **1. Why the Correct Answer is Right (Half-life of the drug):** The concept of **Steady State** refers to the condition where the rate of drug elimination equals the rate of drug administration. In clinical pharmacokinetics, the time taken to reach this state is determined solely by the **elimination half-life ($t_{1/2}$)** of the drug. * It takes approximately **4 to 5 half-lives** to reach steady state (94% at 4 half-lives, 97% at 5 half-lives). * This rule applies regardless of the dose or the frequency of administration, as the rate of accumulation is a function of the drug's inherent clearance rate. **2. Why the Other Options are Incorrect:** * **Route of Administration (A):** This affects the *bioavailability* and the *speed* at which the initial peak concentration is reached, but it does not change the time required to achieve a stable equilibrium in the plasma. * **Dose Interval (C) & Dosage (D):** While these factors determine the **plateau concentration level** (i.e., how high or low the steady-state concentration will be), they do not influence the **time** taken to get there. Whether you give a large dose or a small dose, it will still take 4–5 half-lives to stabilize. **3. Clinical Pearls for NEET-PG:** * **Loading Dose:** If a rapid therapeutic effect is needed (e.g., Lidocaine in arrhythmias), a loading dose is given to bypass the 4–5 half-life delay. However, it does *not* reach a true steady state faster; it simply reaches the target concentration sooner. * **Washout Period:** Similarly, it takes 4–5 half-lives for a drug to be completely eliminated from the body after stopping the regimen. * **Formula:** $Steady State \approx 4.3 \times t_{1/2}$. * **Rule of Thumb:** For any drug following first-order kinetics, the time to steady state is independent of the dose.

Q: What is the therapeutic index of the drug based on the provided dose-response curve (DRC)?

21. ***21*** - The **therapeutic index (TI)** is calculated as **TD50/ED50**, where TD50 is the dose causing toxicity in 50% of subjects and ED50 is the dose producing therapeutic effect in 50% of subjects. - A TI of 21 indicates a **relatively safe drug** with a good margin between therapeutic and toxic doses, allowing for safer clinical use. *8* - This value represents a **narrow therapeutic window**, suggesting the drug would be too close to toxic levels for safe clinical use. - A TI of 8 would indicate **higher risk of toxicity** at therapeutic doses, making it less desirable than the calculated value of 21. *128* - This value is **too high** based on the dose-response curve data, likely representing an overestimation of the safety margin. - A TI of 128 would suggest an **extremely wide therapeutic window**, which doesn't match the typical pharmacokinetic profile shown in the curve. *1024* - This represents an **unrealistically high therapeutic index** that would indicate virtually no risk of toxicity at therapeutic doses. - Such a high TI value is **inconsistent** with the dose-response relationship demonstrated in the provided curve data.

Question 1

Which pathological state alters the volume of distribution of many drugs?

Accepted Answer

Congestive heart failure

Answer

Septicemia

Answer

Duodenal ulcers

Answer

Hypertension

Question 2

Which of the following terms best describes a drug that blocks the action of adrenaline at its receptors by occupying those receptors without activating them?

Accepted Answer

Pharmacologic antagonist

Answer

Non-competitive antagonist

Answer

Physiologic antagonist

Answer

Chemical antagonist

Question 3

Which of the following statements about biotransformation is untrue?

Accepted Answer

More fat-soluble metabolites are formed.

Answer

Inactive metabolites are formed.

Answer

Active metabolites are formed.

Answer

More water-soluble metabolites are formed.

Question 4

Which of the following drugs has the least oral bioavailability?

Accepted Answer

d-tubocurarine

Answer

Morphine

Answer

Ampicillin

Answer

Phenytoin

Question 5

The time required to reach the steady state after a dosage regimen depends on which of the following?

Accepted Answer

Half-life of the drug

Answer

Route of Administration

Answer

Dose interval

Answer

Dosage of the drug

Question 6

In drug metabolism, what is the primary role of the hepatic cytochrome P-450 system?

Accepted Answer

Mediating Phase I reactions such as hydrolysis, oxidation, and reduction.

Answer

Mediating Phase II reactions such as conjugation and synthesis.

Answer

Mediating both Phase I and Phase II reactions.

Answer

Converting hydrophilic metabolites into lipophilic metabolites.

Question 7

What is the therapeutic index of the drug based on the provided dose-response curve (DRC)?

Accepted Answer

21

Answer

8

Answer

128

Answer

1024

Question 8

The pharmacokinetics of Paroxetine include its ability to be easily absorbed after oral administration in healthy volunteers even after food is ingested. Which of the following is TRUE regarding Paroxetine's pharmacokinetics?

Accepted Answer

Less than 1% of the drug is in systemic circulation owing to extensive distribution in body tissues.

Answer

The main portion of the medication resides in systemic circulation.

Answer

Little of the medication is absorbed into the tissues.

Answer

Less than 25% is eliminated by the kidneys.

Question 9

Which of the following most accurately describes the transmembrane signaling process involved in the steroid hormone action?

Accepted Answer

Diffusion across the membrane and binding to an intracellular receptor

Answer

Action on a membrane spanning tyrosine kinase

Answer

Action of a G protein, which activates or inhibits adenylyl cyclase

Answer

Opening of transmembrane ion channels

Question 10

All of the following statements regarding volume of distribution are true except?

Accepted Answer

It is calculated by multiplying the half-life by log base 2.

Answer

Half-life is usually proportional to Vd.

Answer

Skeletal muscle relaxants generally have a low volume of distribution.

Answer

Drugs with high plasma protein binding tend to have a low volume of distribution.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?